HPV and HPV-associated cervical diseases in women, who use hormonal methods of contraception: diagnostic and treatment management of abnormal cytology test result
https://doi.org/10.21518/2079-701X-2019-7-34-38
Abstract
If abnormal cytology test results are identified in the users of hormonal methods of contraception, including a vaginal ring, they should adhere to diagnostic algorithms aimed at identifying and treating HPV-associated cervical diseases. NovaRing vaginal ring is an effective, reliable and safe method of hormonal contraception, including for women who have previously undergone surgical treatment of HSIL.
About the Authors
N. M. Nazarova
Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Nazarova Niso Mirzoevna, Dr. of Sci. (Med.), Leading Researcher.
117997, Russia, Moscow, 4 Oparina str.
K. I. Gusakov
Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Gusakov Kirill Ilyich, a postgraduate student.
117997, Russia, Moscow, 4 Oparina str.
E. G. Sycheva
Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Sycheva Elena Gennadievna, a physician.
117997, Russia, Moscow, 4 Oparina str.
References
1. Tang Y., Zheng L., Yang S. et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in nonvaccinated women. Virology Journal. 2017;14:84.
2. WHO/ICO Information Centre on HPV and Cancer. Russian Federation: Human Papillomavirus and Related Cancers, Fact Sheet 2016 (2016.12.15) [http://www.hpvcentre.net].
3. Wheeler C.M., Hunt W.C., Joste N.E. et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101:475–87
4. De Sanjose S. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol. 2010;11:1048–56.
5. Arbyn M., Tommasino M., Depuydt C., Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol.2014;234(4):431-5.
6. Halec G., Alemany L., Lloveras B. et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4):441-51.
7. http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-key-statistics.
8. http://www.cancer.org/cancer/analcancer/detailedguide/anal-cancer-what-is-keystatistics.
9. Cancer Statistics. Surveillance Epidemiology and End Results, National Cancer Institute. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Retrieved October 22, 2013.
10. Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-42.
11. Katki H.A., Schiffman M., Castle P.E. et al. Fiveyear risk of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis. 2013;17:36–42.
12. Gagea J.C., Huntb W. C., Schiffmana M. et al. Risk Stratification using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a Statewide Surveillance Program. Cancer Epidemiol Biomarkers Prev. 2016;25(1):36–42.
13. Arbyn M., Xu L., Verdoodt F. et al. Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis. Ann Intern Med. 2017;166(2):118-127.
14. Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. ACS-ASCCPASCP Cervical Cancer Guideline Committee. CA Cancer J Clin. 2012;62:147–72.
Review
For citations:
Nazarova NM, Gusakov KI, Sycheva EG. HPV and HPV-associated cervical diseases in women, who use hormonal methods of contraception: diagnostic and treatment management of abnormal cytology test result. Meditsinskiy sovet = Medical Council. 2019;(7):34-38. (In Russ.) https://doi.org/10.21518/2079-701X-2019-7-34-38
Views:
1087
Email this article 